Low and Int 1-risk Myelodysplastic Syndrome
1 clinical trials · Condition
◉ Watch Low and Int 1-risk Myelodysplastic Syndrome
| Record | Firm | Date |
|---|---|---|
| Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome. (NCT01868477) | Novartis Pharmaceuticals | 2014-01-28 |
Track Low and Int 1-risk Myelodysplastic Syndrome automatically
Every clearance here is in the API, with alerts when new ones post.